These payloads activate an internal alarm that can bring immune cells into action. Antibody delivery aims to trigger the alarm near tumors while limiting activation elsewhere.
STING is an intracellular sensor pathway involved in innate immunity. XMT-2056 is a HER2-directed conjugate whose STING agonist activated cancer cells and tumor-resident immune cells in preclinical studies. Its development study must be distinguished from its human trial, which the registry now lists as terminated. STING activation is not equivalent to TLR activation, and tumor-directed delivery does not guarantee freedom from systemic inflammation.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Immune-stimulating antibody conjugate (ISAC), Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/